Author

Y. Wang

Institution: Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China)

Observed institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, University of Chinese Academy of Sciences, Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China)

ORCID: 0000-0003-1806-0004

Observed ORCID: 0000-0003-1806-0004

OpenAlex ID: A5081615525

8MO The efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancer

2022 · S. Lu, H. Pan, et al. · Annals of Oncology · 3

P2.10.13 Sunvozertinib Combined With Bevacizumab in Previously Treated Advanced NSCLC With EGFR Exon 20 Insertion Mutations

2025 · Y. Yu, Y. Zhang, et al. · Journal of Thoracic Oncology · 1

CO214 Model Predictions for Lifetime Health Benefits of Mobocertinib and Current Treatment Options in Post-Platinum Patients with Locally Advanced or Metastatic NSCLC Harboring Egfr Exon 20 Insertion Mutation in China

2023 · G.Y. Zuo, Y. Wang, et al. · Value in Health

MA08.06 Stratifying PD-L1 Expression Level Based on Multimodal Genomic Features for the Prediction of Immunotherapy Benefit in NSCLC

2021 · Y. Wang, Y. Li, et al. · Journal of Thoracic Oncology

Works count: 4

Citation count: 4

H-index: 1

I10-index: